BIO-RAD ($NYSE:BIO): Bio-Rad Laboratories has reported its second quarter FY2023 earnings results, for the period ending June 30 2023. Total revenue for the quarter decreased by 1.4% year-on-year to USD 681.1 million, whilst net income dropped from -927.2 million in the same period the year prior to -1162.2 million.
The stock opened at $402.9 and closed at $401.8, representing a 0.5% decrease from the last closing price of $403.8. Meanwhile, their clinical diagnostics business reported a 1% increase in sales compared to the same period in FY2022. This significant increase in profits was attributed to the company’s ability to control their costs and generate higher revenues across their core business divisions. The company is now focused on expanding their presence in the global markets and continuing to deliver innovative products and services to their customers. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Bio-rad Laboratories. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bio-rad Laboratories. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bio-rad Laboratories. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Bio-rad Laboratories are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Bio-rad Laboratories Stock Fair Value
At GoodWhale, we analyze the financials of BIO-RAD LABORATORIES through our proprietary platform. Our Valuation Line has estimated the intrinsic value of BIO-RAD LABORATORIES’s share to be about $458.0. This is significantly higher than the current market price of $401.8, which indicates that BIO-RAD LABORATORIES’s stock is undervalued by 12.3%. Therefore, now is a great time to invest in the company and benefit from its potentially undervalued stock. More…
Risk Rating Analysis
Star Chart Analysis
The competition in the medical technology industry is fierce. Among the major players are Bio-Rad Laboratories Inc and its competitors Lexagene Holdings Inc, Co-Diagnostics Inc, Suzhou Basecare Medical Corp Ltd. All of these companies are vying for a share of the market by offering innovative products and services.
– Lexagene Holdings Inc ($TSXV:LXG)
Lexagene Holdings Inc is a biotechnology company that develops and commercializes diagnostic solutions for the detection of pathogens. The company has a market cap of 19.42M as of 2022 and a return on equity of -164.09%. The company’s products are used in a variety of industries, including healthcare, agriculture, and food safety.
Co-Diagnostics Inc is a molecular diagnostics company that develops, manufactures, and markets diagnostic tests. The company has a market cap of 103.71M as of 2022 and a return on equity of 12.67%. Co-Diagnostics Inc develops and manufactures diagnostic tests for a range of infectious diseases, including Zika virus, dengue fever, and chikungunya. The company’s products are used by healthcare providers, laboratories, and research institutions around the world.
– Suzhou Basecare Medical Corp Ltd ($SEHK:02170)
With a market cap of 790.49M as of 2022, Suzhou Basecare Medical Corp Ltd has a ROE of -4.34%. The company is engaged in the research and development, production, and sale of medical devices. Its products include surgical gowns, medical masks, and medical gloves.
Bio-Rad Laboratories is a publicly traded company and has shown mixed financial results in the second quarter of FY2023. Total revenue decreased by 1.4% to USD 681.1 million compared to the same period last year, while net income declined to -1162.2 million from -927.2 million the previous year. Despite the decline in net income, Bio-Rad Laboratories remains a potential investment opportunity due to its strong brand recognition and innovative products. Investors should further assess Bio-Rad’s financials and forecasted growth over the coming year to determine if the stock is a viable investment.